Ana Paula Dias Rangel Montenegro

Ana Paula Dias Rangel Montenegro

Auto-generated profile, based on publicly available information

Ana Paula Dias Rangel Montenegro

Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
EFErika Freire
Erika Freire
CDCatarina Brasil D’alva
Catarina Brasil D’alva
MMMayara Ponte Madeira
Mayara Ponte Madeira
GLGrayce Lima
Grayce Lima
AMAna Paula Dias Rangel Montenegro
Ana Paula Dias Rangel Montenegro
B(Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO)
Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO)
Congenital Generalized Lipodystrophy (CGL) is a rare syndrome characterized by the almost total absence of subcutaneous adipose tissue due to the inability of storing lipid in adipocytes. Patients present generalized lack of subcutaneous fat and normal to low weight. They evolve with severe metabolic disorders, non-alcoholic fatty liver disease, early cardiac abnormalities, and infectious complications. Although low body weight is a known risk factor for osteoporosis, it has been reported that type 1 and 2 CGL have a tendency of high bone mineral density (BMD). In this review, we discuss the role of bone marrow tissue, adipokines, and insulin resistance in the setting of the normal to high BMD of CGL patients. Data bases from Pubmed and LILACS were searched, and 113 articles published until 10 April 2021 were obtained. Of these, 76 were excluded for not covering the review topic. A manual search for additional literature was performed using the bibliographies of the studies located. The elucidation of the mechanisms responsible for the increase in BMD in this unique model of insulin resistance may contribute to the understanding of the interrelationships between bone, muscle, and adipose tissue in a pathophysiological and therapeutic perspective.

7 November 2022 in 3 Biotech
Verified
Journal Article
Open access
PDF file
José Ednésio da Cruz FreireJosé Ednésio da Cruz Freire
José Ednésio da Cruz Freire
JJJosé Edvar Monteiro Júnior
José Edvar Monteiro Júnior
DPDaniel Pascoalino Pinheiro
Daniel Pascoalino Pinheiro
GLGrayce Lima
Grayce Lima
CACamila Lopes Do Amaral
Camila Lopes Do Amaral
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
The current outbreak of COVID-19 cases worldwide has been responsible for a significant number of deaths, especially in hospitalized patients suffering from comorbidities, such as obesity, diabetes, hypertension. The disease not only has prompted an interest in the pathophysiology, but also it has propelled a massive race to find new anti-SARS-CoV-2 drugs. In this scenario, known drugs commonly used to treat other diseases have been suggested as alternative or complementary therapeutics. Herein we propose the use of sitagliptin, an inhibitor of dipeptidyl peptidase-4 (DPP4) used to treat type-II diabetes, as an agent to block and inhibit the activity of two proteases, 3CLpro and PLpro, related to the processing of SARS-CoV-2 structural proteins. Inhibition of these proteases may possibly reduce the viral load and infection on the host by hampering the synthesis of new viruses, thus promoting a better outcome. In silico assays consisting in the modeling of the ligand sitagliptin and evaluation of its capacity to interact with 3CLpro and PLpro through the prediction of the ligand bioactivity, molecular docking, overlapping of crystal structures, and molecular dynamic simulations were conducted. The experiments indicate that sitagliptin can interact and bind to both targets. However, this interaction seems to be stronger and more stable to 3CLpro (ΔG = −7.8 kcal mol−1), when compared to PLpro (ΔG = −7.5 kcal mol−1). This study suggests that sitagliptin may be suitable to treat COVID-19 patients, beyond its common use as an anti-diabetic medication. In vivo studies may further support this hypothesis.

1 July 2019 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
CPClarisse Mourão Melo Ponte
Clarisse Mourão Melo Ponte
VFVirgínia Oliveira Fernandes
Virgínia Oliveira Fernandes
CLChristiane Bezerra Rocha Liberato
Christiane Bezerra Rocha Liberato
AMAna Paula Dias Rangel Montenegro
Ana Paula Dias Rangel Montenegro
LBLívia Aline Batista
Lívia Aline Batista
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
Congenital generalized lipodystrophy (CGL) is a rare disorder characterized by the absence of subcutaneous adipose tissue, severe insulin resistance, diabetes mellitus, and cardiovascular complications, including cardiac autonomic neuropathy (CAN), left ventricular hypertrophy (LVH), and atherosclerosis. The present study aimed to access the association between CAN parameters and cardiovascular abnormalities in CGL patients. A cross-sectional study was conducted with 10 CGL patients and 20 healthy controls matched for age, sex, BMI, and pubertal stage. We evaluated clinical, laboratory, and cardiovascular parameters—left ventricular mass index (LVMI), interventricular septum thickness (IVS), systolic and diastolic function determined by two-dimensional transthoracic echocardiography; carotid intimal media thickness (cIMT); and cQT interval. Heart rate variability (HRV) was evaluated by spectral analysis components—high frequency (HF), low frequency (LF), very low frequency (VLF), LF/HF ratio, and total amplitude spectrum (TAS)—and cardiovascular reflexes tests (postural hypotension test, respiratory, orthostatic and Valsalva coefficients). In CGL group, four patients (40%) had LVH and diastolic dysfunction. HF component (parasympathetic control) was lower in LVH patients. CGL patients presented higher values of cIMT and cQT interval than heathy subjects. Inverse association between LVMI and LF (p = 0.011), IVS and LF (p = 0.007), and cIMT and leptin (p < 0.001) were observed, even after adjustments by HOMA-IR, A1c, and blood pressure. In CGL group, there were associations between LMVI and HF component (IC95%: − 1.000; − 00.553), LVMI and TAS (IC95%: − 1.000; − 0.012), and IVS and HF component (IC95%: − 1.000; − 0.371). The association between increased LV mass and parameters of HRV provides possible speculations about the involvement of CAN in the pathophysiology of the cardiac complications, including LVH, in patients with CGL.

17 May 2021 in Revista Brasileira em Promoção da Saúde
Verified
Journal Article
Open access
PDF file
MOMaria Rafaela Martins De Oliveira
Maria Rafaela Martins De Oliveira
MFMatheus Aragão Dias Firmino
Matheus Aragão Dias Firmino
LSLuana Matos De Souza
Luana Matos De Souza
AMAna Paula Dias Rangel Montenegro
Ana Paula Dias Rangel Montenegro
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
ABAlane Nogueira Bezerra
Alane Nogueira Bezerra
Objetivo: Avaliar a qualidade da dieta de crianças e adolescentes com excesso de peso e determinar a relação com fatores de risco cardiometabólico. Métodos: Estudo quantitativo, transversal e analítico, realizado entre dezembro de 2016 e agosto de 2018, com crianças e adolescentes. Coletaram-se variáveis comportamentais (prática de atividade física e tempo de tela), antropométricas (peso, altura, índice de massa corporal, circunferência abdominal e do pescoço) e dietéticas (recordatório de 24 horas) e os dados bioquímicos foram consultados nos prontuários. Avaliou-se a resistência à insulina (RI), usando Homeostasis Model Assessment – Insulin Resistance (HOMA-IR), e a qualidade da dieta, por meio do Índice de Qualidade da Dieta Revisado (IQD-R). Análises realizadas pelos testes de Spearman e Mann-Whitney U, com nível de significância de 5%. Resultados: A amostra incluiu 100 crianças e adolescentes, sendo 71 (71%) do sexo feminino, média de idade de 9,42 ± 2,89 anos. IQD-R apresentou valor médio de 61,16 (IC 95%: 59,14 – 63,19) e nenhum participante apresentou dieta de boa qualidade. Não foram encontradas associações entre o escore do IQD-R e marcadores cardiometabólicos. Observaram-se associações negativas entre os componentes “vegetais totais e leguminosas” e HOMA-IR (r= -0,290), “vegetais verde-escuros, alaranjados e leguminosas” e HOMA-IR (r= -0,333) e “vegetais verde-escuros, alaranjados e leguminosas” com insulina de jejum (r= -0,291). Participantes com mais de três fatores de risco cardiometabólico tiveram pontuação significativamente maior do componente “gordura sólida e açúcar de adição”. Conclusão: Nenhum participante investigado apresentou dieta qualitativamente adequada. A baixa ingestão de vegetais e leguminosas foi associada com marcadores de RI.

13 June 2021 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MMMayara Ponte Madeira
Mayara Ponte Madeira
EFErika Freire
Erika Freire
VFVirginia Oliveira Fernandes
Virginia Oliveira Fernandes
GLGrayce Lima
Grayce Lima
IMIvana da Ponte Melo
Ivana da Ponte Melo
B(Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO)
Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO)
Background: A new strain of human coronavirus (HCoV) spread rapidly around the world. Diabetes and obesity are associated with a worse prognosis in these patients. Congenital Generalized Lipodystrophy (CGL) patients generally have poorly controlled diabetes and require extremely high doses of insulin. There is no documentation in the literature of cases of COVID in CGL patients. Thus, we aimed to evaluate the prevalence of SARS-CoV-2 infection in CGL patients, and the association of their clinical and metabolic characteristics and outcomes. Methods: This is a cross-sectional study carried out between July and October 2020. Clinical data collected were respiratory or other flu-like symptoms, need of hospitalization in the last three months, CGL comorbidities, and medications in use. Cholesterol, triglycerides, glycohemoglobin A1c levels, anti-SARS-CoV-2 antibodies and nasopharyngeal swab for RT-qPCR were also obtained in all CGL patients. Mann-Whitney U test was used to analyze the characteristics of the participants, verifying the non-adherence of the data to the Gaussian distribution. In investigating the association between categorical variables, we used Pearson's chi-square test and Fisher's exact test. A significance level of 5% was adopted. Results: Twenty-two CGL patients were assessed. Eight subjects (36.4%) had reactive anti-SARS-CoV-2 antibodies. Only one of these, also presented detectable RT-qPCR. Five individuals (62.5%) were women, median age of 13.5 years (1 to 37). Symptoms like fever, malaise, nausea, diarrhea and chest pain were present, and all asymptomatic patients were children. All subjects had inadequate metabolic control, with no difference between groups. Among positive individuals there was no difference between those with AGPAT2 (75%) and BSCL2 gene mutations (25%) (p > 0.05). No patient needed hospitalization or died. Conclusions: We described a high prevalence of SARS-CoV-2 infection in CGL patients with a good outcome in all of them. These findings suggest that at least young CGL patients infected by SARS-COV-2 are not at higher risk of poor outcome, despite known severe metabolic comorbidities.

1 January 2025 in Revista Paulista de Pediatria
Verified
Journal Article
Open access
PDF file
MSMayara Teixeira Alexandrino Sales
Mayara Teixeira Alexandrino Sales
RBRebeca Costa Castelo Branco
Rebeca Costa Castelo Branco
CGCarlos Henrique Paiva Granjeiro
Carlos Henrique Paiva Granjeiro
MSMilena Silva Sousa
Milena Silva Sousa
LALuciana Felipe Férrer Aragão
Luciana Felipe Férrer Aragão
AQAna Rosa Pinto Quidute
Ana Rosa Pinto Quidute
Objective To describe a case of multiple endocrine neoplasia type 1 in the pediatric age group and its molecular diagnosis.